StockData

BioLineRx vs Ernexa Therapeutics

BLRX and ERNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLRX and ERNA compare

Ernexa Therapeutics scores higher on the StockData Score (6 against 3 for BioLineRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLRXERNA
Size and price
Market cap–$2.7M
Share price$1.12$1.63
Change, 1 year−65.3%−95.7%
Change, 5 years−98.9%−100.0%
Beta (5Y)1.562.80
Employees205
StockData Score
Total score36 (better)
Valuation score01 (better)
Growth score1 (better)0
Performance score00
Health score25 (better)
Dividend score00
Valuation
P/B–0.8×
Growth
Revenue growth (TTM)−95.9%–
Profitability
Gross margin80.5%–
Operating margin−872%–
FCF margin−686%–
Return on equity–−321%
Return on invested capital−59.7%–
Financial health
Debt / equity0.33 (better)0.00
Interest coverage−8.0×–
Current ratio1.202.01 (better)
Altman Z-score–−62.69
Piotroski F-score–3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%–
Held by insiders0.39%–
Insider net buying, 12 months–$2.0M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.